A total of 551 pts with newly diagnosed CML-CP received imatinib (IM) 400 mg orally once
daily as part of the IRIS study (O'Brien et al, NEJM 2003). We now summarize the correlation …

Background: Correlation between IM plasma level and clinical response has been
previously reported [Larson et al., Picard et al.]. TOPS is an open-label, randomized …

Recent long term clinical outcome data have now established 400 mg/d of imatinib as the
first line treatment for newly diagnosed patients with CML. We report here the kinetics of …

We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic
phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) …

Aims This study was designed to investigate the biochemical and physiological covariates or
comedications that affect the pharmacokinetics of imatinib mesylate in patients with chronic …

CML patients who obtain a complete cytogenetic response (CCgR) may harbor different
degrees of molecular disease, which are associated with different progression-free survival …

Cytogenetic and molecular responses to standard-dose imatinib (IM) were correlated with
trough IM plasma levels for 78 patients with chronic myeloid leukemia (CML) after a …

BACKGROUND Variable responses to imatinib, in the treatment of chronic myeloid leukemia
(CML), are incompletely understood. Previous studies focused on cellular mechanisms of …

Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …